Cargando…

Can metabolomic signature foster precision medicine approaches in nonalcoholic fatty liver disease arena?

Detalles Bibliográficos
Autor principal:	Lonardo, Amedeo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	AME Publishing Company 2022
Materias:	Editorial
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9745633/ https://www.ncbi.nlm.nih.gov/pubmed/36523943 http://dx.doi.org/10.21037/hbsn-22-459

Ejemplares similares

History of Nonalcoholic Fatty Liver Disease
por: Lonardo, Amedeo, et al.
Publicado: (2020)

Nonalcoholic fatty liver disease: Evolving paradigms
por: Lonardo, Amedeo, et al.
Publicado: (2017)

Nonalcoholic Fatty Liver Disease and Chronic Kidney Disease: Epidemiology, Pathogenesis, and Clinical and Research Implications
por: Lonardo, Amedeo, et al.
Publicado: (2022)

Nonalcoholic Fatty Liver Disease
por: Filipović, Branka, et al.
Publicado: (2018)

Perspectives on Precision Medicine Approaches to NAFLD Diagnosis and Management
por: Lonardo, Amedeo, et al.
Publicado: (2021)

Glucagon-Like Peptide-1 Receptor Agonists for Treatment of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis: An Updated Meta-Analysis of Randomized Controlled Trials
por: Mantovani, Alessandro, et al.
Publicado: (2021)

Diabetes and Nonalcoholic Fatty Liver Disease
por: Kantartzis, Konstantinos, et al.
Publicado: (2012)

Arenas of Crisis
por: Strasser, Irene, et al.
Publicado: (2021)

Fostering precision psychiatry through bioinformatics
por: Fernandes, Brisa S., et al.
Publicado: (2021)

Diet and Lifestyle in Nonalcoholic Fatty Liver Disease
por: Martínez-Beamonte, Roberto, et al.
Publicado: (2020)

Implications of comorbidities in nonalcoholic fatty liver disease
por: Song, Sherlot Juan, et al.
Publicado: (2023)

Methodological Tools for Exploring Novel Biopharmaceutical Approaches to the Metabolic Syndrome and Related Disorders: A Commentary on: Translational Research Methods in Diabetes, Obesity, and Nonalcoholic Fatty Liver Disease. A Focus on Early Phase Clinical Drug Development, Second Edition
por: Lonardo, Amedeo, et al.
Publicado: (2020)

Recent advances in nonalcoholic fatty liver disease metabolomics
por: Kim, Hwi Young
Publicado: (2021)

Innovative Molecular Target and Therapeutic Approaches in Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis (NAFLD/NASH) 2.0
por: Vairetti, Mariapia, et al.
Publicado: (2022)

Nonalcoholic Fatty Liver Disease: Its Mechanisms and Complications
por: El Ouaamari, Abdelfattah, et al.
Publicado: (2013)

Noninvasive Markers for the Diagnosis of Nonalcoholic Fatty Liver Disease
por: Kim, Sang Yong
Publicado: (2013)

The utility of ezetimibe therapy in nonalcoholic fatty liver disease
por: Jun, Baek Gyu, et al.
Publicado: (2019)

Role of cenicriviroc in the management of nonalcoholic fatty liver disease
por: Neokosmidis, Georgios, et al.
Publicado: (2018)

Treating Nonalcoholic Fatty Liver Disease From the Outside In?
por: Flynn, Charles R.
Publicado: (2019)

Imaging methods in the assessment of nonalcoholic fatty liver disease
por: Parente, Daniella Braz
Publicado: (2020)

NAFLD as a Sexual Dimorphic Disease: Role of Gender and Reproductive Status in the Development and Progression of Nonalcoholic Fatty Liver Disease and Inherent Cardiovascular Risk
por: Ballestri, Stefano, et al.
Publicado: (2017)

Personalized medicine in nonalcoholic fatty liver disease
por: Pirola, Carlos J., et al.
Publicado: (2022)

The effect of moderate alcohol consumption on nonalcoholic fatty liver disease
por: Park, Ji-Won, et al.
Publicado: (2023)

Transition of an acronym from nonalcoholic fatty liver disease to metabolic dysfunction-associated fatty liver disease
por: Alam, Shahinul, et al.
Publicado: (2021)

Update cognition of nonalcoholic fatty liver disease/metabolism‐associated fatty liver disease
por: Gu, Weijun, et al.
Publicado: (2022)

Precision medicine in nonalcoholic fatty liver disease: New therapeutic insights from genetics and systems biology
por: Sookoian, Silvia, et al.
Publicado: (2020)

Serum metabolomic analysis of the effect of exercise on nonalcoholic fatty liver disease
por: Li, Jia, et al.
Publicado: (2019)

Serum metabolome alterations in patients with early nonalcoholic fatty liver disease
por: Wang, Xuemei, et al.
Publicado: (2022)

Do Nonalcoholic Fatty Liver Disease and Fetuin-A Play Different Roles in Symptomatic Coronary Artery Disease and Peripheral Arterial Disease?
por: Nascimbeni, Fabio, et al.
Publicado: (2018)

Emerging role of obeticholic acid in the management of nonalcoholic fatty liver disease
por: Makri, Evangelia, et al.
Publicado: (2016)

It’s Ready for Targeting Muscle in Nonalcoholic Fatty Liver in This Era of Aging
por: Joo, Sae Kyung, et al.
Publicado: (2019)

Nonalcoholic fatty liver disease in lean subjects: Prognosis, outcomes and management
por: Chrysavgis, Lampros, et al.
Publicado: (2020)

Sarcopenia as a Novel Risk Factor for Nonalcoholic Fatty Liver Disease
por: Noh, Junghyun
Publicado: (2020)

Probiotics for treatment of nonalcoholic fatty liver disease: It is worth a try
por: Ren, Tian-Yi, et al.
Publicado: (2021)

Nonalcoholic fatty liver disease – a growing public health problem
por: Mikolašević, Ivana, et al.
Publicado: (2021)

The role of magnetic resonance elastography in the evaluation of nonalcoholic fatty liver disease
por: Idilman, Ilkay S., et al.
Publicado: (2023)

Sarcopenic Obesity, the Possible Culprit for Nonalcoholic Fatty Liver Disease or Fibrosis
por: Kang, Seong Hee, et al.
Publicado: (2023)

Clustering NAFLD: phenotypes of nonalcoholic fatty liver disease and their differing trajectories
por: Kantartzis, Konstantinos, et al.
Publicado: (2023)

Aerobic and Resistance Exercise: Synergistic Influence for Nonalcoholic Fatty Liver Disease
por: Chun, Ho Soo
Publicado: (2023)

Liver Imaging in Precision Medicine
por: Dong, Jiahong, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_7a4holgobngeh8g2958oppmk63